Announcements Trials
Browse Landscape

Phase

Phase 3 40Phase 2 37Phase 4 16Phase 1/2 6Phase 1 4Phase NA 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 7INDUSTRY 4NIH 3

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4Genitourinary 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

peginesatide 2hematide 2iron isomaltoside 1000 1LY2787106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Anemia × Clear all
NCT01340976 2018-10-03

A Phase 1 Study of LY2787106 in Cancer and Anemia

Eli Lilly and Company

Phase 1 Completed
33 enrolled 18 charts
Classical hematology

Anemia

NCT01280240 2013-06-04

PK-CIA-06

Pharmacosmos A/S

Phase 1 Completed
11 enrolled
Classical hematology

Anemia, Neoplasms

NCT00097747 2012-12-21

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Affymax

Phase 1 Completed
28 enrolled
Classical hematologyGenitourinary

Anemia, Kidney Failure, Chronic, Neoplasms, Renal Insufficiency, Chronic

NCT00629876 2011-12-01

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Takeda

Phase 1 Terminated
2 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡